DexCom, Inc. (NASDAQ:DXCM) Director Bridgette P. Heller Sells 352 Shares

DexCom, Inc. (NASDAQ:DXCM) Director Bridgette P. Heller sold 352 shares of the business’s stock in a transaction on Monday, March 17th. The shares were sold at an average price of $70.33, for a total transaction of $24,756.16. Following the sale, the director now owns 22,997 shares of the company’s stock, valued at approximately $1,617,379.01. This represents a 1.51 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link.

DexCom Price Performance

Shares of DXCM traded up $2.68 during midday trading on Wednesday, hitting $73.38. 4,302,408 shares of the company traded hands, compared to its average volume of 3,887,227. The firm has a 50 day moving average of $83.64 and a 200-day moving average of $76.95. DexCom, Inc. has a 52 week low of $62.34 and a 52 week high of $142.00. The stock has a market cap of $28.67 billion, a price-to-earnings ratio of 51.31, a PEG ratio of 2.30 and a beta of 1.28. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.28 and a current ratio of 1.47.

DexCom (NASDAQ:DXCM) last released its quarterly earnings results on Thursday, February 13th. The medical device company reported $0.45 earnings per share for the quarter, missing the consensus estimate of $0.50 by ($0.05). DexCom had a net margin of 14.29% and a return on equity of 30.14%. On average, analysts forecast that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts have weighed in on the stock. Citigroup boosted their target price on shares of DexCom from $101.00 to $104.00 and gave the company a “buy” rating in a research note on Tuesday, March 4th. Morgan Stanley upped their price objective on DexCom from $75.00 to $82.00 and gave the stock an “equal weight” rating in a research note on Friday, February 14th. Canaccord Genuity Group upped their price objective on DexCom from $99.00 to $103.00 and gave the stock a “buy” rating in a research note on Friday, February 14th. Wells Fargo & Company restated an “overweight” rating on shares of DexCom in a research note on Saturday, March 8th. Finally, Redburn Atlantic upgraded DexCom from a “neutral” rating to a “buy” rating and upped their price objective for the stock from $85.00 to $115.00 in a research note on Monday, February 3rd. Four research analysts have rated the stock with a hold rating, thirteen have given a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $99.82.

Institutional Investors Weigh In On DexCom

Hedge funds have recently bought and sold shares of the business. Empowered Funds LLC lifted its holdings in shares of DexCom by 6.1% in the 3rd quarter. Empowered Funds LLC now owns 5,847 shares of the medical device company’s stock valued at $392,000 after acquiring an additional 335 shares during the last quarter. Mutual of America Capital Management LLC increased its position in shares of DexCom by 3.8% during the 3rd quarter. Mutual of America Capital Management LLC now owns 57,138 shares of the medical device company’s stock valued at $3,831,000 after purchasing an additional 2,084 shares during the last quarter. Thrivent Financial for Lutherans raised its holdings in DexCom by 44.2% during the 3rd quarter. Thrivent Financial for Lutherans now owns 314,102 shares of the medical device company’s stock valued at $21,058,000 after buying an additional 96,274 shares during the period. Swiss National Bank boosted its stake in DexCom by 3.4% during the third quarter. Swiss National Bank now owns 1,180,400 shares of the medical device company’s stock worth $79,134,000 after buying an additional 39,000 shares during the period. Finally, Fifth Third Wealth Advisors LLC increased its position in DexCom by 305.4% during the third quarter. Fifth Third Wealth Advisors LLC now owns 29,646 shares of the medical device company’s stock valued at $1,987,000 after acquiring an additional 22,334 shares during the last quarter. Hedge funds and other institutional investors own 97.75% of the company’s stock.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.